Interestingly, synergy was seen with high-dose, but not low-dose, anti-PD-L1 therapy highlighting a dose-dependent factor in the ability of ICPI to overcome either the intrinsic tumour-mediated immunosuppression or OV-induced checkpoint upregulation (54). This evidence concerns the gene CD274 and neoplasm.